Key terms
About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ABBV news
Today
2:02pm ET
Fake Botox Fight Sends AbbVie (NASDAQ:ABBV) Up Fractionally
Yesterday
2:30am ET
AbbVie Stock (NYSE:ABBV): Humira Leads Market with 96% Share
Apr 12
7:32am ET
AbbVie presents results from ongoing Phase 3 study of oral atogepant
Apr 08
3:50am ET
Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), AbbVie (ABBV) and Immunome (IMNM)
Apr 08
3:31am ET
Analysts Conflicted on These Healthcare Names: AbbVie (ABBV), Universal Health (UHS) and Teladoc (TDOC)
Apr 05
1:36am ET
AbbVie (NYSE:ABBV) Trims EPS Outlook, Stock Drops
Apr 03
7:27am ET
Oppenheimer more bullish on Aldeyra, upgrades to Outperform
Apr 03
5:20am ET
Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV) and AbbVie (ABBV)
Apr 02
11:16am ET
AbbVie put volume heavy and directionally bearish
Apr 01
5:58am ET
This Biopharma Stock Outperformed MSTR and SMCI in March 2024
Mar 26
8:24pm ET
AbbVie price target raised to $195 from $185 at Barclays
Mar 25
9:10pm ET
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE) and AbbVie (ABBV)
Mar 25
2:44pm ET
Fly Insider: NextNav, Akamai among week’s notable insider trades
Mar 25
8:35am ET
AbbVie to acquire Landos Biopharma for $20.42 per share in cash plus CVR
Mar 25
8:34am ET
AbbVie to acquire Landos Biopharma got $20.42 per share in cash
Mar 25
8:32am ET
AbbVie to acquire Landos Biopharma for $20.42 per share in cash
Mar 24
5:04am ET
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Legend Biotech (LEGN)
Mar 24
5:03am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV) and Gilead Sciences (GILD)
Mar 22
3:06pm ET
AbbVie confirms FDA grants full approval for Elahere for certain ovarian cancers
Mar 22
2:34pm ET
FDA approves mirvetuximab soravtansine-gynx for certain cancers
Mar 22
6:42am ET
AbbVie price target raised to $190 from $188 at Guggenheim
Mar 15
12:03pm ET
JPMorgan biotech/pharma analysts hold an analyst/industry conference call
Mar 12
8:40am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Incyte (INCY), AbbVie (ABBV) and ACADIA Pharmaceuticals (ACAD)
Mar 05
8:08am ET
Allergan Aesthetics announces FDA approval of JUVEDERM VOLUMA XC
Mar 05
7:16am ET
AbbVie makes milestone payment to Dragonfly after dosing in solid tumor trial
Feb 28
6:06am ET
AbbVie, OSE Immunotherapeutics enter pact to develop OSE-230
Feb 27
4:08pm ET
Regenxbio expects cash to fund operations into 2H25
Feb 27
7:49am ET
AbbVie’s epcoritamab granted priority review by FDA in follicular lymphoma
Feb 27
7:48am ET
Genmab, AbbVie announce FDA priority review for sBLA
Feb 26
11:45am ET
Truist biotech analysts hold an analyst/industry conference call
Feb 26
4:55am ET
Truist biotech analysts hold an analyst/industry conference call
No recent press releases are available for ABBV
ABBV Financials
Key terms
Ad Feedback
ABBV Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ABBV Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
